Gene therapy is rapidly emerging as a transformative approach for retinitis pigmentosa treatment and other retinal degenerative disorders, with the eye providing an ideal environment for targeted interventions. Notably, the retina became the first tissue to receive a retinitis pigmentosa gene therapy FDA approval in the United States, marking a pivotal milestone in the retinal gene therapy market. To date, only one therapy, LUXTURNA retinitis pigmentosa, developed by Spark Therapeutics, has been approved, highlighting both progress and the unmet need for a broader retinitis pigmentosa cure.
Approved by the FDA in December 2017, LUXTURNA is a one-time gene therapy f...
